Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | August 29, 2012

When PET Fails

We want absolutes; things we can depend on; certainties in an unfortunately uncertain world. It’s the kind of faith we put into positron emission tomography/computed tomography (PET/CT), even when it’s not warranted.

More than a year ago, the German Institute for Quality and Efficiency in Health Care released a study concluding that there was a dearth of support for the use of PET/CT as a reliable aid in diagnosing or monitoring for the return of melanoma. A systematic search found no published studies to indicate the relevance of PET or PET/CT in either primary staging or in the detection of recurrences of malignant melanoma. Nor was any research uncovered indicating the prognostic accuracy of this technique.

In the absence of documented failures or successes, PET/CT continues to be used by some physicians to stage melanoma or monitor patients for its recurrence. Its results are used, consequently, to ease patient worries, sometimes incorrectly.

So it was that a long-time friend of mine, who had been battling melanoma for the past six years, received a PET/CT, embraced its negative findings, then weeks later encountered symptoms that led him to undergo a brain CT, which revealed a large tumor in his parietal and temporal lobes.

In mainstream medical practice, FDG-PET is considered essential for staging and monitoring patients battling cancers such as lymphoma and that of the lung, according to Michael Vannier, M.D., professor of radiology at the University of Chicago. But PET has specific and significant limitations. These are often related to the type of disease, the isotopic agent and the size of the lesion, Vannier explained.

“We sometimes find that PET has been used inappropriately for certain tumor types. Renal cell cancer and prostate cancer are notoriously difficult to image with FDG-PET,” he told me.

Add melanoma to that list.

When PET/CT is used to do what it cannot do effectively, it may be an expression of an old maxim –  that when all you have is a hammer, everything looks like a nail.

In this age of dwindling resources, we need to be a little pickier about what we hammer. The financial costs of doing so indiscriminately are high. Yet they pale when compared to the emotional price paid by patients whose belief in a bright future is unwarranted.

Related Content

The artificial intelligence-driven Caption Guidance software guides point of care ultrasound (POCUS) users to get optimal cardiac ultrasound images. The AI software is an example of a FDA-cleared software that is helping improve imaging, even when used by less experienced users.

The artificial intelligence-driven Caption Guidance software guides point of care ultrasound (POCUS) users to get optimal cardiac ultrasound images. The AI software is an example of a FDA-cleared software that is helping improve imaging, even when used by less experienced users.

Feature | Artificial Intelligence | September 29, 2020 | Joe Fornadel, J.D., and Wes Moran, J.D.
The number of Federal Drug Administration (FDA)-approved AI-based algorithms is significant and has grown at a steady
he Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule.

Getty Images

News | Radiation Oncology | September 29, 2020
September 29, 2020 — On Sept.
The FDA Center for Devices and Radiological Health's COVID-19 response by the numbers between January 1 and September 18, 2020.

The FDA Center for Devices and Radiological Health's COVID-19 response by the numbers between January 1 and September 18, 2020. Graphic courtesy of FDA

News | Coronavirus (COVID-19) | September 29, 2020
September 29, 2020 — On September 28, FDA Commissioner of Food and Drugs...
Important milestone demonstrates the unrivalled experience, technological innovation and global market leadership of IBA and its clinical partners
News | Proton Therapy | September 25, 2020
September 25, 2020 — IBA (Ion Beam Applications SA) announced that more than 100,000 patients have now been treated w
Lung and respiratory health pioneer paves way for more precise care of complex respiratory conditions
News | Artificial Intelligence | September 25, 2020
September 25, 2020 — VIDA Diagnostics, Inc. announced that it has received 510(k) clearance from the Food and Drug Ad